Secondly, several previous trials investigating BRAF-mutated colorectal cancer primarily reported subgroup analyses from landmark studies with limited sample sizes, which could affect the reliability of the meta-analytical estimates; however, meta-regression also showed no substantial effect. This evidence concerns the gene BRAF and colorectal cancer.